Serum biomarkers for glioblastoma multiforme

Area of Science:

• Oncology
• Biomarker Discovery
• Neuroscience

Background:

• Glioblastoma Multiforme (GBM) diagnosis and prognosis currently lack sufficient non-invasive tools.
• Serum biomarkers offer a potential avenue for less invasive disease assessment and monitoring.
• MicroRNAs (miRNAs) are increasingly recognized as key players in cancer biology and potential biomarkers.

Purpose of the Study:

• To review the current landscape of serum biomarkers for Glioblastoma Multiforme.
• To highlight the role of microRNAs and other candidate biomarkers in GBM diagnosis and prognosis.
• To assess the readiness of these biomarkers for clinical implementation.

Main Methods:

• Literature review of studies investigating serum biomarkers in Glioblastoma Multiforme.
• Analysis of reported associations between specific biomarkers (e.g., miRNAs, GFAP, YLK-40) and GBM characteristics.
• Evaluation of the diagnostic and prognostic potential of identified biomarkers.

Main Results:

• Numerous microRNAs have shown differential expression in Glioblastoma Multiforme patients.
• Associations identified between specific microRNAs and clinical outcomes like Progression Free Survival and Overall Survival.
• Other biomarkers including Glial Fibrillary Acid Protein (GFAP), cytokines, and YLK-40 are also under investigation.

Conclusions:

• Serum biomarkers, particularly microRNAs, show significant potential for non-invasive Glioblastoma Multiforme diagnosis and monitoring.
• Current evidence suggests associations with disease recurrence and patient survival.
• Larger, well-designed studies are necessary to validate these findings and enable routine clinical use.